Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
NY-ESO-1 immunotherapy for ovarian cancer

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.04.16
Views: 2774

Dr Kunle Odunsi - Roswell Park Cancer Institute, Buffalo, USA

Dr Kunle Odunsi talks to ecancertv at AACR 2016 about his research into courses of immunotherapy against ovarian cancer.

Having established in previous research the link between T cell infiltration of a tumour to improved patient survival, Dr Odunsi has sought to determine an ovarian cancer antigen - in this case NY-ESO-1 - to prolong patient remission and promote anti-tumour immune response in patients.

Historically, cancer cells have evaded immune response via manipulation of cellular checkpoints PD1 and IDO, which limits T cell proliferation. 

By combining these targets with CAR-T cell technologies, Dr Odunsi hopes to extend T cell lifespans in patients, and provide a long-lasting anti-tumour effector T cell population.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation